Januvia (Sitagliptin) is an oral antidiabetic medicine belonging to class dipeptidyl peptidase-4 (DPP-4) inhibitor, manufactured by Merck & Co., was approved by the U.S. Food and Drug Administration (FDA) in 2006. In 2007, the FDA approved a variation of Januvia called Janumet, which is a combination of sitagliptin and metformin and is also made by Merck.
Sitagliptin is an anti-diabetic drug that works by increasing the levels of natural substances called incretins. Incretins help to control blood sugar by increasing insulin release, especially after a meal. They also decrease the amount of sugar your liver makes. It works by regulating the levels of insulin your body produces after eating.